This Article Full Text Full Text (PDF) CME: Take the course for this article: The Role of ErbB Inhibitors in Trastuzumab Resistance eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, K. D. Search for Related Content PubMed PubMed Citation Articles by Miller, K. D.

The Role of ErbB Inhibitors in Trastuzumab Resistance

Indiana University School of Medicine, Indianapolis, Indiana, USA

Correspondence: Kathy D. Miller, M.D., Indiana University School of Medicine, Indiana Cancer Pavilion, 535 Barnhill Drive, RT-473, Indianapolis, Indiana 46202, USA. Telephone: 317-274-0920; Fax: 317-274-3646; e-mail: kathmill{at}iupui.edu

The ErbB family of receptors and ligands is a complex, delicately balanced system involved in the growth and differentiation of normal human cells as well as neoplasms. Targeting this system with therapies that inhibit ErbB receptor activity in cancer patients has been somewhat successful, but resistance to ErbB inhibitor monotherapy is substantial. An understanding of the biology of ErbB receptor inhibitors is necessary to determine how best to utilize them in treatment regimens. Experimental evidence has provided valuable insights regarding mechanisms involved in resistance, and indicates that resistance can be reversed in some models. Ongoing studies in patients are evaluating whether agents that target both the epidermal growth factor (EGFR, ErbB-1) and ErbB-2 (HER-2) receptors can prevent or delay resistance in patients with metastatic breast cancer that overexpresses HER-2. With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected.

Key Words. Breast cancer • Resistance • Trastuzumab • Tyrosine kinase receptor

This article has been cited by other articles:

				P. Seve, J. Mackey, S. Isaac, O. Tredan, P.-J. Souquet, M. Perol, R. Lai, A. Voloch, and C. Dumontet Class III {beta}-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel Mol. Cancer Ther., December 1, 2005; 4(12): 2001 - 2007. [Abstract] [Full Text] [PDF]

				D. Escuin, E. R. Kline, and P. Giannakakou Both Microtubule-Stabilizing and Microtubule-Destabilizing Drugs Inhibit Hypoxia-Inducible Factor-1{alpha} Accumulation and Activity by Disrupting Microtubule Function Cancer Res., October 1, 2005; 65(19): 9021 - 9028. [Abstract] [Full Text] [PDF]

				V. R. Fantin, M. J. Berardi, H. Babbe, M. V. Michelman, C. M. Manning, and P. Leder A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells Cancer Res., August 1, 2005; 65(15): 6891 - 6900. [Abstract] [Full Text] [PDF]

				M. D. Pegram Molecular Determinants of Trastuzumab Response/Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159. [Full Text] [PDF]

				M. D. Pegram, R. Pietras, A. Bajamonde, P. Klein, and G. Fyfe Targeted Therapy: Wave of the Future J. Clin. Oncol., March 10, 2005; 23(8): 1776 - 1781. [Full Text] [PDF]

				D. W. Blayney, B. W. McGuire, S. E. Cruickshank, and D. H. Johnson Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Non-Small Cell Lung Cancer and Non-Hodgkin's Lymphoma Oncologist, February 1, 2005; 10(2): 138 - 149. [Abstract] [Full Text] [PDF]